Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
about
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsGefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsEfficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface areaSynthesis of BODIPY-Peptide Conjugates for Fluorescence Labeling of EGFR Overexpressing Cells.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceC4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinomaNext-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.Circulating Cell-Free Tumour DNA in the Management of Cancer.Rapid Optimization of Mcl-1 Inhibitors using Stapled Peptide Libraries Including Non-Natural Side Chains.Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupSecond-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients.Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways.Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Synthesis and biological evaluation of peptide-conjugated phthalocyanine photosensitizers with highly hydrophilic modifications.Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.Twenty-One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer.Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer.
P2860
Q26745776-2F5068C7-7F1A-4CD0-8608-2BC0C3314882Q26799467-01FC6DBA-64CC-4AF3-98D9-ACB780F4E88DQ28074716-CC013E36-9C90-4D6B-9649-28F771A4BC11Q28086768-445E2B3A-574E-44AE-A3B9-9B4F81CD1534Q28540120-DE878ADF-E338-4C1B-9A00-83F0BAD27AE8Q28547357-37696CC4-BBE2-4019-9D5C-B9C385592809Q33733770-86BF06D3-6175-43C9-9545-291427F4F679Q33898658-15CE7D3D-FD60-4E53-87EF-54CBEEC42F98Q34011705-353FC4D9-2DA4-40E3-A90E-0D5E987AAB1DQ34031219-6EDAB6F2-0D35-4DF5-BD90-DAB06242AB2EQ34092436-2EB53F26-F4A1-46E9-AEC0-D200C176B234Q34248282-043B0F26-368A-4D4B-BCE1-B0D7E069AC17Q34276149-F6FF3099-E379-41FF-AFBA-4CDAA8A85FE7Q34346624-0CECA4AB-8AA9-4F5D-A0A3-91C01BC956CAQ35814162-D52DCB61-9750-45DC-8980-68907875DAEEQ35917117-1DE0765F-86E2-4BCF-BF9A-7A5DD555EE18Q35958288-493A305C-64DA-43D7-945C-07C8512742B2Q36082772-1F2CE291-4D4D-4A04-BF60-25ACA7BC8742Q36640486-55693B65-04E7-4FDA-8666-96AC9840981AQ36807886-85591A0F-ED71-467D-AE07-ABA26D43CFE3Q37109499-77BD6CEA-8663-4EA4-BC8A-21C32576C35BQ37330932-8EE934C7-7EFB-4C51-AECC-15010EE058DAQ37365512-98ABF5B4-162C-44F3-801A-A42726B183FDQ38349157-16711198-555F-4CAD-9D9C-88E230AFA939Q38728165-982665E1-868D-4309-B7DB-E4E0BC731EEFQ38767492-84DFC06D-BC2B-4588-BCF4-C8462F0C2DD5Q38787862-15F27075-D2D5-4214-B1E3-FFA1E072ED07Q39025910-EC50EBF2-AA03-4C6C-8A40-6FB24BF3C13DQ45065769-739CF8AF-1224-4F5C-B4B9-BA73596EC10CQ47261717-961F4BE0-4C41-4F2F-A893-2014D863BA15Q47811425-61ED5308-EB4E-4E27-B652-08F22B0B1891Q52145217-6CE067E2-DCA8-4236-80BD-B9E233C6022FQ54110132-08E07619-67BB-45AB-848B-51263E0086F9Q55041728-8AAE5576-60DF-4FAD-BAE1-DF70B42644F5Q55177170-542BECA2-8227-4CC9-8DD3-1E4C0F4CA630
P2860
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Epidermal growth factor recept ...... nd mutation-positive patients.
@ast
Epidermal growth factor recept ...... nd mutation-positive patients.
@en
Epidermal growth factor recept ...... nd mutation-positive patients.
@nl
type
label
Epidermal growth factor recept ...... nd mutation-positive patients.
@ast
Epidermal growth factor recept ...... nd mutation-positive patients.
@en
Epidermal growth factor recept ...... nd mutation-positive patients.
@nl
prefLabel
Epidermal growth factor recept ...... nd mutation-positive patients.
@ast
Epidermal growth factor recept ...... nd mutation-positive patients.
@en
Epidermal growth factor recept ...... nd mutation-positive patients.
@nl
P2093
P1476
Epidermal growth factor recept ...... nd mutation-positive patients.
@en
P2093
Gregory J Tsongalis
James R Rigas
Konstantin H Dragnev
Monic Roengvoraphoj
P304
P356
10.1016/J.CTRV.2013.05.001
P577
2013-06-12T00:00:00Z